Medacta Group SA
Medacta Group SA Fundamental Analysis
Medacta Group SA (MEDGF) shows strong financial fundamentals with a PE ratio of 14.93, profit margin of 14.69%, and ROE of 23.61%. The company generates $0.6B in annual revenue with strong year-over-year growth of 15.62%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze MEDGF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentMEDGF demonstrates superior asset utilization.
Valuation Score
ExcellentMEDGF trades at attractive valuation levels.
Growth Score
ExcellentMEDGF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentMEDGF maintains a strong and stable balance sheet.
Profitability Score
ModerateMEDGF maintains healthy but balanced margins.
Key Financial Metrics
Is MEDGF Expensive or Cheap?
P/E Ratio
MEDGF trades at 14.93 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, MEDGF's PEG of 0.58 indicates potential undervaluation.
Price to Book
The market values Medacta Group SA at 3.34 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 7.38 times EBITDA. This is generally considered low.
How Well Does MEDGF Make Money?
Net Profit Margin
For every $100 in sales, Medacta Group SA keeps $14.69 as profit after all expenses.
Operating Margin
Core operations generate 16.35 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $23.61 in profit for every $100 of shareholder equity.
ROA
Medacta Group SA generates $11.03 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medacta Group SA produces operating cash flow of $138.06M, showing steady but balanced cash generation.
Free Cash Flow
Medacta Group SA produces free cash flow of $42.43M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.13 in free cash annually.
FCF Yield
MEDGF converts 3.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.93
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.58
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.34
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.19
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.60
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.39
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.24
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How MEDGF Stacks Against Its Sector Peers
| Metric | MEDGF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.93 | 29.45 | Better (Cheaper) |
| ROE | 23.61% | 779.00% | Weak |
| Net Margin | 14.69% | -24930.00% (disorted) | Strong |
| Debt/Equity | 0.60 | 0.26 | Weak (High Leverage) |
| Current Ratio | 2.39 | 4.65 | Strong Liquidity |
| ROA | 11.03% | -19333.00% (disorted) | Strong |
MEDGF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medacta Group SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
90.17%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
514.73%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
151.35%
Industry Style: Defensive, Growth, Innovation
High Growth